Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction ...
Sep 24, 2013
0
0
Patches giving oestrogen through the skin could be an easy and safe alternative to the hormone therapies used to treat prostate cancer, according to new research published in the Lancet Oncology, today (Monday).
Mar 4, 2013
0
0
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October ...
Oct 10, 2012
0
0
(HealthDay)—An integrative model incorporating cancer care into primary care is recommended for addressing the increasing burden of cancer control, according to a commission piece published online Sept. 29 in The Lancet ...
Oct 1, 2015
0
7
Giving some bowel cancer patients six weeks of chemotherapy before surgery can significantly shrink their tumour, making it easier to remove and potentially reducing the chances of the cancer coming back, according to results ...
Nov 1, 2012
0
0
Remarkable improvements in survival from childhood cancer have taken place in high- income countries over the past 50 years, but further progress is being threatened by increasingly strict research regulations and insufficient ...
Feb 19, 2013
0
0
The study, published in The Lancet Oncology, is the first ever assessment of the effect of cancer screening in rural sub-Saharan Africa, and the authors are hopeful that their work, which is on-going, will ultimately show ...
Jan 30, 2013
0
0
Emeritus Professor Sheila Payne from the International Observatory on End of Life Care at Lancaster University helped conduct the study commissioned by the European Association for Palliative Care (EAPC) and published in ...
Sep 5, 2017
0
1
In a review article published in The Lancet Oncology, Susu Yan, Ph.D., and Thomas Bortfeld, Ph.D., from the Biophysics Division of MGH's Department of Radiation Oncology, and co-authors describe the evolution of proton therapy ...
Jun 8, 2023
0
10
Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor ...
Dec 1, 2020
0
0
